AOD-9604 + BPC-157 (5mg + 5mg)
A combination of two peptides with complementary action: AOD-9604 (GH fragment 176-191) exclusively targets lipolysis without anabolic or hyperglycemic side effects, while BPC-157 (Body Protection Compound) accelerates tissue repair, reduces inflammation, and improves microcirculation. Ideal for body recomposition with simultaneous joint/tendon support.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
**AOD-9604** activates lipolysis via β3-adrenergic receptors, increasing the release of fatty acids from adipocytes without affecting glucose metabolism. Simultaneously, **BPC-157** upregulates VEGF (Vascular Endothelial Growth Factor), promotes angiogenesis, and accelerates the repair of tendons, ligaments, and muscle tissues via the FAK-paxillin pathway. The synergistic action provides simultaneous lipolysis and tissue regeneration.
Quick Start
- AOD-9604: 300 mcg SC, 1x/day (morning, fasted)
- BPC-157: 250 mcg SC, 2x/day (morning + evening)
- Cycle: 8–12 weeks
- Storage: Refrigerator 2–8°C after reconstitution
Dosing Table — AOD-9604 + BPC-157 Stack
Route: Subcutaneous (SC) | Frequency: See per peptide
| Week | Dose | Units (per injection) |
|---|---|---|
| 1–2 | 250mcg AOD / 250mcg BPC x2 | 10 Units (0.10 mL) |
| 3–8 | 300mcg AOD / 250mcg BPC x2 | 12 Units (0.12 mL) |
| 9–12 | 300mcg AOD / 250mcg BPC x2 | 12 Units (0.12 mL) |
AOD-9604: 1x/day subcutaneously in the morning on an empty stomach (30 minutes before breakfast). BPC-157: 2x/day (morning + evening), near the injury site if applicable.
Related compounds
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
AOD-9604 (5 mg)
BPC-157 (5 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- AOD-9604 (5 mg): Add 2.0 mL of bacteriostatic water → 2.5 mg/mL (2,500 mcg/mL).
- BPC-157 (5 mg): Add 2.0 mL of bacteriostatic water → 2.5 mg/mL (2,500 mcg/mL).
- Gently swirl — do not shake. Store in the refrigerator (2–8 °C).
Protocol Overview
- AOD-9604 is a modified fragment (amino acids 176-191) of human growth hormone, designed to retain its lipolytic properties without anabolic effects.
- BPC-157 (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) derived from gastric juice, known for its potent regenerative properties.
- Their combination simultaneously targets: lipolysis + tissue repair + anti-inflammatory action.
Dosing Protocol
- AOD-9604: 250–300 mcg subcutaneously, 1x/day, in the morning (fasted, 30 minutes before food).
- BPC-157: 250 mcg subcutaneously, 2x/day (morning + evening). For local injuries, inject near the site.
- Cycle: 8–12 weeks, followed by a 4-week pause.
- Break between cycles: 4-week pause between cycles to prevent metabolic adaptation.
Washout & Cycle Restart
When can I restart?
4-week pause between cycles to prevent metabolic adaptation.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized powder: −20 °C (up to 24 months).
- Reconstituted solution: 2–8 °C (refrigerator), use within 4 weeks.
- Protect from light and repeated freeze-thaw cycles.
Important Notes
- AOD-9604 does not affect IGF-1 levels or blood glucose.
- BPC-157 acts via the FAK-paxillin pathway and the NO system.
- The combination does not interact negatively — the two peptides have entirely different mechanisms.
- For athletes: check the WADA list — AOD-9604 is NOT included but its status may change.
Potential Benefits & Side Effects
Potential Benefits:
- Targeted lipolysis with no effect on muscle mass
- Accelerated healing of tendons and ligaments
- Anti-inflammatory action (reduction of TNF-α, IL-6)
- Improved microcirculation (angiogenesis)
- Safe combination without drug interactions
- Does not affect IGF-1, glucose, or cortisol
Potential Side Effects:
- Mild redness/itching at the injection site (transient)
- Rare: headache during the first few days
- BPC-157: rarely nausea at high doses
- No serious adverse events have been reported in research protocols
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Failed clinical trials — questionable efficacy
The Phase III obesity trial did not meet primary endpoint. Long-term safety as injectable has not been documented (GRAS only for oral use).
📄 Metabolic Pharmaceuticals (Clinical Trial Data)Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010References
- AOD9604 stimulates lipid metabolism in vivo — Heffernan MA et al., Obesity Research, 2001.
View Source - Stable gastric pentadecapeptide BPC 157 and wound healing — Sikiric P et al., Curr Pharm Des, 2018.
View Source - BPC 157 and angiogenesis — Seiwerth S et al., J Physiol Pharmacol, 2014.
View Source
Recommended Supplements
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
GRAS (oral) — Not approved as an injectable
FDA GRAS (oral only)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →